Type-II Variation: Waive in-vivo study by providing in-vitro data? [Study As­sess­ment]

posted by Relaxation  – Germany, 2024-07-04 14:19 (309 d 11:31 ago) – Posting: # 24061
Views: 2,183

Hello everybody

❝ However all of the conditions required for a Class III waiver have to be met and this goes beyond simply showing dissolution similarity.


And as I happen to have the ICH M-9 just in front of me for other reasons, I cite chapter 3 first paragraph:
"A drug product is eligible for a BCS-based biowaiver ... drug product is the same dosage form and strength"

Best regards!

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
66 visitors (0 registered, 66 guests [including 4 identified bots]).
Forum time: 01:51 CEST (Europe/Vienna)

Freedom is always and exclusively
freedom for the one
who thinks differently.    Rosa Luxemburg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5